Prevalence of the C536T Mutation in the Tissue Factor Pathway Inhibitor (TFPI) Gene among Patients with Venous Thromboembolic Disease

• References

• 1 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
• 2 Kleesiek K, Schmidt M, Gotting C, Brinkmann T, Prohaska W. A first mutation in the human tissue factor pathway inhibitor gene encoding [P151L] TFPI. Blood 1998; 92: 3976-7.
• 3 Kleesiek K, Schmidt M, Gotting C, Schwenz B, Lange S, Muller-Berghaus G, Brinkmann T, Prohaska W. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
• 4 Evans GD, Langdown J, Brown K, Baglin TP. The C536T transition in the Tissue Factor Pathway Inhibitor gene is not a common cause of venous thromboembolic disease in the UK population. Thromb Haemost 2000; 83: 5 .
• 5 Gonzalez-Conejero R, Lozano ML, Corral J, Martinez C, Vicente V. The TFPI 536C →■ T mutation is not associated with increased risk for venous or arterial thrombosis. Thromb Haemost 2000; 83: 787-8.
• 6 De Stefano V, Zappacosta B, Persichilli S, Rossi E, Casorelli I, Paciaroni K, Chiusolo P, Leone AM, Giardina B, Leone G. Prevalence of mild hyper-homocysteinemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G202 0A) in Italian patients with venous throm-boembolic disease. Br J Haematol 1999; 106: 564-8.